A Phase 2 interventional study of VX-561 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 79th largest by enrollment, is one of 10 that started in 2016, is one of 17 in phase 2, and was the 45th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 10 started in 2016.
This study's enrollment of 11 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 114th largest by enrollment of the 116 interventional ones that give a count, is one of 15 that started in 2016, is one of 21 in phase 2, and was the 60th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.
This is a randomized, parallel-group, double-blind, placebo controlled multicenter study to evaluate the safety and efficacy of CTP-656 in CF patients with CFTR gating mutations, compared to Kalydeco, for a total of 28 days. Subjects will be randomized to receive either double-blind CTP-656 or placebo, or open-label Kalydeco.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: VX-561
Drug: VX-561
Drug: VX-561
Drug: IVA
Drug: Placebo
Change From Baseline in Sweat Chloride at Day 28
Time frame: From baseline at Day 28
Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28
Time frame: From baseline at Day 28
Change From Baseline in Cystic Fibrosis Questionnaire-Respiratory Domain (CFQ-R) at Day 28
Time frame: From baseline at Day 28
| Milestone | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor |
|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 3 |
| Completed | 2 | 2 | 2 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Day 1 up to Day 35. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VX-561 20 mg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| VX-561 100 mg | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| VX-561 150 mg | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Ivacaftor | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Event | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor |
|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 1/2 | 2/2 | 0/3 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/2 | 2/2 | 0/3 |
| Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 1/2 | 1/2 | 0/3 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/2 | 1/2 | 0/3 |
| Increased bronchial secretionRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Nasal oedemaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Pharyngeal oedemaRespiratory, thoracic and mediastinal disorders | 1/2 | 0/2 | 0/2 | 0/2 | 0/3 |
| Age, Continuous(years) | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor | Total |
|---|---|---|---|---|---|---|
| Mean | 24.0 ± 1.41 | 20.0 ± 1.41 | 19.5 ± 2.12 | 29.0 ± 2.83 | 19.7 ± 0.58 | 22.2 ± 4.00 |
| Sex: Female, Male(Participants) | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 2 | 2 | 9 |
| Male | 0 | 1 | 0 | 0 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 2 | 2 | 2 | 1 | 3 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 2 | 2 | 2 | 3 | 11 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Sweat Chloride(millimole per liter (mmol/L)) | VX-561 20 mg | VX-561 100 mg | VX-561 150 mg | Placebo | Ivacaftor | Total |
|---|---|---|---|---|---|---|
| Mean | 59.25 ± 16.617 | 82.25 ± 27.931 | 61.50 ± 32.527 | 36.50 ± 29.698 | 71.25 ± 37.830 | 62.15 ± 27.355 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2016 to primary completion in Aug 2017, 8 months.
Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Aug 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →